NCT07531095
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07531095
Title Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) (DeLLphi-313)
Acronym DeLLphi-313
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.